Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Abstract Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who h...

Полное описание

Библиографические подробности

Главные авторы:	Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Kaori Ochiai, Daisuke Nakayama
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2020-03-01
Серии:	Cardiology and Therapy
Предметы:	Anticoagulant Dabigatran Emergency surgery Hemorrhage Idarucizumab Japan
Online-ссылка:	https://doi.org/10.1007/s40119-020-00165-8
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!